Inspirion Delivery Technologies LLC

Sponsors of opioid analgesics capped off a largely unsuccessful 2018 with the US FDA's rejection of SpecGx 's immediate-release (IR) reformulation of Roxicodone (oxycodone hydrochloride) MNK-812, a

Defeated in its effort to win US FDA approval of its immediate-release oxycodone product, Pharmaceutical Manufacturing Research Services Inc. is now trying to block other opioids with abuse deterrent

Mallinckrodt PLC is seeking to replace its immediate release oxycodone tablets with an abuse-deterrent version, MNK-812. But it may have a hard time getting advisory committee backing as the US FDA a

The US FDA will ask its external experts whether the decreased likelihood of intranasal abuse with Pain Therapeutics Inc. ’s long-acting opioid Remoxy ER (oxycodone extended-release) is outweighed